Endocrine PharmacologyPioglitazone-induced body weight gain is prevented by combined administration with the lipoprotein lipase activator NO-1886
Introduction
The antidiabetic agent pioglitazone is thought to promote the differentiation of adipocytes, convert large-type hypertrophic adipocytes into small-type adipocytes, and to increase insulin activity through peroxisome proliferator-activated receptor-γ (PPARγ) activation (de Souza et al., 2001, Spiegelman, 1998). In addition, thiazolidinediones have also been shown to improve the serum levels of several adipocytokines, such as adiponectin and TNF-α, in type 2 diabetic patients (Miyazaki and DeFronzo, 2008, Oz et al., 2008). However, as a result of the enhanced adipocyte differentiation, pioglitazone treatment has been shown to be associated with body weight gain in obese animals and type 2 diabetic patients (Boden and Zhang, 2006, de Souza et al., 2001, Hermansen and Mortensen, 2007, Miyazaki and DeFronzo, 2008). As the mechanism underlying the body weight gain, Hallakou et al. (1997) explained that pioglitazone stimulated the expression of genes involved in lipid metabolism and induced a large increase in glucose utilization in the adipose tissue. Obesity aggravates diabetes and promotes cardiovascular diseases and atherosclerosis (Allison et al., 1999, Fontaine et al., 2003, Kadowaki and Yamauchi, 2005), and the body-weight-increasing action of pioglitazone is a disadvantage in diabetic patients. On the other hand, the lipoprotein lipase (LPL) activator NO-1886 (Kusunoki et al., 2002, Tsutsumi et al., 1993, Tsutsumi et al., 1995) is known to improve both obesity and insulin resistance in obese animals (Hara et al., 1998, Kusunoki et al., 2000).
In this study, we investigated the effect of the simultaneous administration of pioglitazone, which induces a body weight gain, and NO-1886, which has an anti-obesity action, on the body weight and insulin resistance of obese rats.
Section snippets
Materials
NO-1886 (4-diethoxyphosphorylmethyl-N-(4-bromo-2-cyanophenyl) benzamide; ibrolipim), was obtained from Otsuka Pharmaceutical Factory, Inc. (Naruto, Tokushima, Japan). Pioglitazone was obtained from Takeda Chemicals Industries, Ltd. (Osaka, Japan). All other chemicals used in this study were high-grade, commercially available products.
Animal experiments
Male SD rats aged 6–7 weeks old and weighing 180–200 g, were obtained from Japan SLC, Inc. (Shizuoka, Japan). The animals were maintained under a 12-h light–dark
Body weight, visceral fat weight, and food consumption
The body weight in the high-fat diet group was generally higher than that in the normal group. The body weight in the pioglitazone group was significantly higher than that in the normal diet group over a period of 7 weeks during the study period (week 9 to week 16). In contrast, the body weight in the NO-1886 group was significantly lower than that in the pioglitazone group during the last 4 weeks (week 12 to week 16). The body weight in the pioglitazone + NO-1886 group was significantly lower than
Discussion
Pioglitazone is a useful therapeutic agent for the treatment of type 2 diabetes and is widely used in clinical settings (Aronoff et al., 2000, Dormandy et al., 2005, Einhorn et al., 2000, Kawamori et al., 2007, Schernthaner et al., 2004). However, several studies have suggested that thiazolidinediones induce body weight gain (Boden and Zhang, 2006, Hermansen and Mortensen, 2007, Miyazaki and DeFronzo, 2008). In this context, the LPL activator NO-1886 improves obesity and insulin resistance (
Conclusions
The addition of NO-1886 counteracted the pioglitazone-induced body weight gain in obese rats fed a high-fat diet. The combined administration of pioglitazone and NO-1886 also ameliorated insulin resistance in obese animals more prominently than either compound alone. Thus, the combined administration of pioglitazone and NO-1886 may be of great benefit for the treatment of type 2 diabetic patients.
Acknowledgments
The authors thank the Takeda Pharmaceutical Co., Ltd. and the Otsuka Pharmaceutical Factory Inc. for providing the pioglitazone and NO-1886, respectively, without accepting compensation.
References (26)
- et al.
Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomized controlled trial
Lancet
(2005) - et al.
Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study
Clin. Ther.
(2000) - et al.
Thiazolidinediones enhance sodium-coupled bicarbonate absorption from renal proximal tubules via PPARγ-dependent nongenomic signaling
Cell Metab.
(2011) - et al.
The actions of a novel lipoprotein lipase activator, NO-1886, in hypertriglyceridemic fructose-fed rats
Metabolism
(1998) - et al.
NO-1886 (ibrolipim), a lipoprotein lipase-promoting agent, accelerates the expression of UCP3 messenger RNA and ameliorates obesity in ovariectomized rats
Metabolism
(2006) - et al.
Hepatic safety profile and glycemic control of pioglitazone in more than 20,000 patients with type 2 diabetes mellitus: postmarketing surveillance study in Japan
Diabetes Res. Clin. Pract.
(2007) - et al.
A lipoprotein lipase activator, NO-1886 prevents impaired endothelium-dependent relaxation of aorta caused by exercise in aged rats
Exp. Gerontol.
(2002) - et al.
NO-1886 inhibits size of adipocytes, suppresses plasma levels of tumor necrosis factor-α and free fatty acids, improves glucose metabolism in high-fat/high-sucrose-fed miniature pigs
Pharmacol. Res.
(2004) - et al.
Annual deaths attributable to obesity in the United States
JAMA
(1999) - et al.
Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes
Diabetes Care
(2000)